What they were paid
Taysha Gene Therapies Director Compensation Table · all 2 fiscal years held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $50,500 | $157,978 | $232,607 | — | $441,085 |
| FY2024 | $50,292 | $156,027 | $231,334 | $0 | $437,653 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Taysha Gene Therapies, Inc. DEF 14A filed April 22, 2026, accession 0001193125-26-168525, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Taysha Gene Therapies pays directors a $40,000 cash retainer.
Committees
FY2025 · as the proxy prints themAudit · Nominating/Governance
The rest of the Taysha Gene Therapies board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Alison Long, M.D., Ph.D | Independent Director | $462,502 |
| Phillip B. Donenberg, CPA | Independent Director | $445,585 |
| Sean P. Nolan | Chair of the Board | $0 |
| Sukumar Nagendran, M.D | Director | $0 |
The full Taysha Gene Therapies compensation record
free company briefThis page is one director within Taysha Gene Therapies's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat